About 400 reports

Top ## players hold majority of stake in the market ##.

  • Targeted Therapy
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.

I THINK THE FIRST ONE WILL BE THE MOST DEMANDED ONE.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

I THINK THE FIRST ONE WILL BE THE MOST DEMANDED ONE.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

National Institute of Neurological Disorders and Stroke.

  • Targeted Therapy
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.
  • Treatment Options by Kinase Domain Mutations

The FDA also states that it may cause heart problems, severe constricting of blood vessels, blood clots, stroke, or liver problems.

  • Targeted Therapy
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Patients in the ERASURE study were randomized ##:##:## to receive subcutaneous Cosentyx ##mg, ##mg, or placebo, whereas the FIXTURE trial had an additional comparative arm of etanercept ##mg dosed twice weekly (##:##:##:##).

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Novartis AG
  • 1.3 PARP INHIBITOR

Rucaparib is a top-of-the-line pharmaceutical preparation for the repair polymerase of DNA polymerase-## (PARP-##) poly-ADP.

  • Targeted Therapy
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

Impact: ## Low; ## High F.

  • Targeted Therapy
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Flamel Technologies S.A.
  • Pfizer Inc.

EUROPEAN NEUROLOGY; ##(SUPPL ##):##-##.

  • Targeted Therapy
  • United States
  • Forecast
  • Biogen Idec Inc.
  • Novartis AG

The risks of tamoxifen therapy include endometrial cancer, deep vein thrombosis, pulmonary embolism, and stroke.

  • Cancer
  • Targeted Therapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

One patient, with pre-existing cardiovascular risk factors, had a fatal event of hemorrhagic stroke caused by a ruptured aneurysm while receiving upadacitinib ##mg.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

During Solo-## and Solo-## patients were randomized ##:##:## to receive either placebo, Dupixent ##mg once weekly or ##mg Dupixent every other week with a placebo in-between.

  • Targeted Therapy
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apricus Biosciences, Inc.

The number of COPD mortalities is expected to increase in the coming decades more than that of other chronic diseases, including heart disease and stroke.

  • Targeted Therapy
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG

An analysis of ##, ## patients with RA found an incidence rate of cardiovascular complications such as myocardial infarction or stroke of ##%.

  • Targeted Therapy
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

The risks of tamoxifen therapy include endometrial cancer, deep vein thrombosis, pulmonary embolism, and stroke.

  • Targeted Therapy
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

National Institute of Neurological Disorder and Stroke.

  • Targeted Therapy
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Sanofi S.A.

Involvement of TNF & its Receptor in Neurodegenerative Disorders ##. ## Alzheimer’s Diseases ##. ## Parkinson’s Diseases ##. ## Ischemic Stroke ##. ## Multiple Sclerosis ##.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • World
  • MARKETED MAB PRODUCTS, SOLIRIS
  • 5.8 SOLIRIS (ECULIZUMAB)

If left untreated, aHUS can lead to progressive kidney failure and is associated with increased risk of stroke and death.

  • Targeted Therapy
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Genentech, Inc.
  • Johnson & Johnson

TWO NON-MELANOMA SKIN ##. ##. ##. ## Safety Pipeline Assessment CANCERS AND TWO MAJOR ADVERSE CARDIOVASCULAR EVENTS, INCLUDING A FATAL STROKE, WERE REGISTERED IN THE BARICITINIB ##MG ARM.

  • Targeted Therapy
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group

RA patients are at an increased risk of cardiovascular events such as myocardial infarction and stroke.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Galapagos NV
  • 3.1 GLOBAL PARP INHIBITOR MARKET BY VALUE
  • 2.3.4 PARP Inhibitor Development

Global Market Analysis ##. ## GLOBAL PARP INHIBITOR MARKET BY VALUE Overall, ## unique PARP inhibitors are identified under clinical/ preclinical development; of these, eight (##%) are being developed for oncological indications, two (##%) are under development for stroke and one

  • Targeted Therapy
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

You can easily book an appointment with one online.

  • Targeted Therapy
  • Hoffmann-La Roche Inc.
  • ImmunoGen, Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Some of the side effects are stroke, heart problems, severe high blood pressure, vision problems, serious bleeding and fertility issues in women, kidney problems, and nausea.

  • Targeted Therapy
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • 3.4 Soliris (eculizumab)

If left untreated, aHUS can lead to progressive kidney failure and is associated with increased risk of stroke and death.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Side effects caused by NSAIDs incldue heartburn, stomach upset, stomach ulcers, risk of blood clots, heart attack, and stroke.

  • Targeted Therapy
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Remicade group

RMD OPEN; ##(SUPPL ##): E##.

  • Targeted Therapy
  • United States
  • Ampio Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.

NOTABLY, SUTENT AND NEXAVAR HAVE BEEN ASSOCIATED WITH INCREASED RISK OF STROKE (JANG ET AL., 2015).

  • Targeted Therapy
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • Roche Group

There were more adjudicated stroke events with odanacatib than with placebo.

  • Targeted Therapy
  • Market Size
  • Amgen Inc.
  • Merck & Co., Inc.
  • Uni-Bio Science Group Limited

Drug-related deaths were observed in ##. ##% of ## patients and included hepatic failure (n=##), stroke (n=##), and perforation (n=##).

  • Targeted Therapy
  • United States
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.

MEDICINE; ##(##): ##-##.

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.